BACM
RIGL icon

Blue Arrow Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Blue Arrow Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-45,000
Closed -$1.02M – 198
2014
Q4 		$1.02M Sell
45,000
-20,000
-31% -$405K 0.12% 143
2014
Q3 		$1.26M Buy
65,000
+60,000
+1,200% +$1.69M 0.14% 139
2014
Q2 		$182K Buy
+5,000
New +$170K 0.02% 133

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Blue Arrow Capital Management's RIGL Position: Q1 2015 in Review

Blue Arrow Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q1 2015, closing a stake of 45,000 shares — an estimated $1.02M sold.

Blue Arrow Capital Management first reported a position in RIGL in Q2 2014 and held it in 3 quarters. The position peaked at $1.26M in Q3 2014. 113 funds tracked by Wall St. Rank hold RIGL as of Q1 2015.

  • Blue Arrow Capital Management reported no remaining Rigel Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Blue Arrow Capital Management sold 45,000 Rigel Pharmaceuticals shares in Q1 2015, an estimated $1.02M.
  • Blue Arrow Capital Management first reported a position in Rigel Pharmaceuticals in Q2 2014 and held it in 3 quarters.
  • Blue Arrow Capital Management's Rigel Pharmaceuticals position peaked at $1.26M in Q3 2014.
  • 113 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2015.

Based on Blue Arrow Capital Management's 13F filing for Q1 2015, filed 15 May 2015.